Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

361 results about "Membrane potential" patented technology

Membrane potential (also transmembrane potential or membrane voltage) is the difference in electric potential between the interior and the exterior of a biological cell. With respect to the exterior of the cell, typical values of membrane potential, normally given in units of millivolts and denoted as mV, ranges from –40 mV to –80 mV.

Methods of wound care and treatment

Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP

Compositions and methods for treating cystic fibrosis

InactiveUS20100303917A1Increased mucus secretionReduce airflowBiocidePowder deliveryTobramycinCell membrane
Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and / or synergy with tobramycin for treating bacterial infection, and use and / or synergy with a bronchiodilator. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (like, membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions).
Owner:REVALESIO CORP

Compositions and methods for treating asthma and other lung disorders

Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent.
Owner:REVALESIO CORP

Compositions and methods for treating digestive disorders

Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating digestive disorders or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said digestive disorders by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids and therapeutic compositions.
Owner:REVALESIO CORP

Compositions and methods for treating cystic fibrosis

Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and / or synergy with tobramycin for treating bacterial infection, and use and / or synergy with a bronchiodilator. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (like, membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions).
Owner:REVALESIO CORP

Compositions and methods for treating inflammation

Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating inflammation or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP

Methods of wound care and treatment

Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP

Compositions and methods for treating asthma and other lung disorders

Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential and / or conductance, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination therapies comprising administration of the electrokinetically generated fluids with at least one additional therapeutic agent.
Owner:REVALESIO CORP

Compositions and methods for treating inflammation

Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating inflammation or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP

Compositions and methods for treating multiple sclerosis

Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP

Compositions and methods for treatment of neurodegenerative diseases

Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., multiple sclerosis (MS), Parkinson's disease (PD), Alzheimer's disease (AD)) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential and / or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP

Compositions and methods for treating multiple sclerosis

Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP

Memristor-based neuron circuit

ActiveCN106845634ARealize integrated discharge functionImplement time encodingPhysical realisationInformation processingSynapse
The invention discloses a memristor-based neuron circuit. According to the neuron circuit, partially volatile bipolar resistive transition devices are selected and used as memristors of a synapse array, and a volatile resistive transition device is selected and used as a memristor for expressing membrane potential of neurons, so that the neuron circuit is formed; and synapse basis units are arranged. The neuron circuit can realize an integral discharge function in biological neurons and express local graded potentials; and synapses have partial volatility, can express spike-timing-dependent plasticity, and have great similarity with biological neurons and synapses in the aspects of information storage, transmission and processing. According to the neuron circuit, the basic units can be provided for hardware to simulate a cerebral neural network structure; the technical problems of neuron discharge time delay, difficulty in realizing high-density integration and the like in the prior art are solved; and the neuron circuit can be used for constructing a brain-like information processing system, can quickly process a large amount of information in parallel, and has a greatly high application value in realizing a cerebral neurologic calculation network.
Owner:HUAZHONG UNIV OF SCI & TECH

Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Particular aspects of the present invention provide compositions and methods suitable for modulation of at least one of cellular membrane potential and cellular membrane conductivity. Additional aspects provide compositions and methods suitable for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically altered solutions to impart electrochemical and / or conformational changes in membranous structures (e.g., membrane proteins, receptors and / or other components) including G-protein coupled receptors (GPCRs), G-proteins, and / or intracellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).
Owner:REVALESIO CORP

Optogenetic probes for measuring membrane potential

The invention provides methods, cells and constructs for optical measurement of membrane potential. These methods can be used in cells that are not accessible to presently available methods using electrodes. The methods can be directed to, for example, high-throughput drug screening assays to determine agents that can affect membrane potential of a target cell.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Autonomous Learning Dynamic Artificial Neural Computing Device and Brain Inspired System

A hierarchical information processing system is disclosed having a plurality of artificial neurons, comprised of binary logic gates, and interconnected through a second plurality of dynamic artificial synapses, intended to simulate or extend the function of a biological nervous system. The system is capable of approximation, autonomous learning and strengthening of formerly learned input patterns. The system learns by simulated Synaptic Time Dependent Plasticity, commonly abbreviated to STDP. Each artificial neuron consisting of a soma circuit and a plurality of synapse circuits, whereby the soma membrane potential, the soma threshold value, the synapse strength and the Post Synaptic Potential at each synapse are expressed as values in binary registers, which are dynamically determined from certain aspects of input pulse timing, previous strength value and output pulse feedback.
Owner:BRAINCHIP INC

Izhikevich neural network synchronous discharging simulation platform based on FPGA

The invention provides an Izhikevich neural network synchronous discharging simulation platform based on an FPGA. The simulation platform comprises an FPGA neural network computing processor and an upper computer which are connected with each other. The FPGA neural network computing processor comprises an FPGA chip, an off-chip memorizer array and an Ethernet communication module, wherein the FPGA chip receives an upper computer control signal output by the off-chip memorizer array, and receives a presynaptic membrane potential signal output by the off-chip memorizer array. The upper computer is in communication with the FPGA chip and the off-chip memorizer array through a VB programming realization man-machine operating interface and the Ethernet communication module, and a neural network model is established on the FPGA chip through Verilog HDL language programming. The Izhikevich neural network synchronous discharging simulation platform has the advantages that the hardware modeling of the phenotype and physiological type neural network model is achieved through an animal-free experiment serving as a biological neural network on the basis of an FPGA neural network experiment platform conducting computation at a high speed, and the consistency with true biological nerve cells on the time scale can be achieved.
Owner:TIANJIN UNIV

Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Particular aspects of the present invention provide compositions and methods for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically generated solutions to impart electrochemical and / or conformational changes in membranous structures (e.g., membrane and / or membrane proteins, receptors or other components) including but not limited to G-protein coupled receptors (GPCRs) and / or G-proteins, and intracellular junctions. In particular embodiments, the electrokinetically generated solutions or compositions are gas-enriched and / or comprise other therapeutic agents. Other embodiments include particular therapeutic methods comprising administration or formulations of the therapeutic compositions, and in various combination treatments.
Owner:REVALESIO CORP

Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures

Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized gas-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Further provided are the methods of making the electrokinetically-altered ionic aqueous fluid compositions. Particular aspects provide for regulating or modulating intracellular signal transduction associated by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular methods of producing the electrokinetically-altered fluids. The electrokinetically-altered fluid compositions and methods of producing the fluid include electrokinetically-altered ionic aqueous fluids optionally in the form of solvated electrons stabilized, at least in part, with molecular gas (e.g., oxygen).
Owner:REVALESIO CORP

AIE bioprobes emitting red or yellow fluorescence

The present subject matter relates to red emitting mitochondria-targeted aggregation induced emission (AIE) probes as an indicator for membrane potential and mouse sperm activity. The present subjectmatter relates to AIE-active fluorescent probes for reactive oxygen species (ROS) detection and related biological applications, such as inflammation imaging and glucose assay, as well as the preparation and application of red fluorescent AIEgens.
Owner:THE HONG KONG UNIV OF SCI & TECH

Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Particular aspects of the present invention provide compositions and methods suitable for modulation of at least one of cellular membrane potential and cellular membrane conductivity. Additional aspects provide compositions and methods suitable for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically altered solutions to impart electrochemical and / or conformational changes in membranous structures (e.g., membrane proteins, receptors and / or other components) including G-protein coupled receptors (GPCRs), G-proteins, and / or intracellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).
Owner:REVALESIO CORP

System and method for in vitro analysis of therapeutic agents

A system and method for in vitro analysis of therapeutic agents comprising a reservoir adapted to hold a therapeutic agent, a first flow cell having a first cell chamber adapted to receive at least a first sample of the therapeutic agent, a second flow cell having a second cell chamber adapted to receive at least a second sample of the therapeutic agent, the first flow cell having a first path length (be′) and the second flow cell having a second path length (be″), the first path length being substantially equal to a sensitivity factor (f)×be″, a membrane chamber having a biological cell membrane therein adapted to receive at least a third sample of the therapeutic agent, the membrane chamber being further adapted to detect the membrane potential of the biological cell membrane; and spectroscopic detection means for detecting the spectral characteristics of the first and second therapeutic agent samples.
Owner:SMITHKLINE BECKMAN CORP

Method and system for measuring membrane potential based on fluorescence polarization

InactiveUS20070254276A1Simple and accurate and inexpensive to performMicrobiological testing/measurementBiological testingFluorescenceFluorescent polarization
A method of determining a membrane potential is disclosed. The method comprises (a) determining a difference in fluorescence polarization of a charged fluorescent probe being distributed across the membrane; and (b) determining a potential of the membrane, wherein the potential is proportional to the difference in the fluorescent polarization.
Owner:SENG ENTERPRISES

High-throughput screen for identifying channel blockers that selectively distinguish transient from persistent sodium channels

A method for identifying a Na+ channel blocker, including providing a cell containing a Na+ channel, demonstrating both a transient and a persistent current. The cell includes a potassium (K+) channel and a Na / K ATPase (Na+ pump). A fluorescent dye is disposed into the well. The fluorescent dye is sensitive to change in cell membrane potential in order to enable optical measurement of cell membrane potential. A Na+ channel blocker, to be identified, is added to the well and a stimulating current is passed through the cell in an amount sufficient to generate an action potential before and after the addition of the Na+ channel blocker. Thereafter, a change in cell membrane potential is optically measured.
Owner:ALLERGAN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products